

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 24 June 2003

Signature: [Signature]
(Thomas J. Englelerner)

Docket No.: 102729-12
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kimberly A. Gillis, et al.

Application No.: 09/997,423

Group Art Unit: N/A

Filed: November 28, 2001

Examiner: Not Yet Assigned

For: EXPRESSION ANALYSIS OF FKBP
NUCLEIC ACIDS AND POLYPEPTIDES
USEFUL IN THE DIAGNOSIS AND
TREATMENT OF PROSTATE CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants and their attorney have become aware of the following publications and information, cited in an International Search Report issued May 22, 2003 during the prosecution of PCT/US01/44536 which corresponds to the above referenced application, and in accordance with 37 CFR §1.97(c), hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form SB/08, and a copy of each publication cited thereon, as well as a copy of the Search Report, are also enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand the Examiner will make an independent evaluation of the cited publications.

The undersigned hereby certifies that each item contained in this disclosure was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 141449.

Dated: June 24, 2003

Respectfully submitted,

By 

Thomas J. Engellenner

Registration No.: 28,411

NUTTER MCCLENNEN & FISH LLP

World Trade Center West

155 Seaport Boulevard

Boston, Massachusetts 02210-2604

(617) 439-2000

(617) 310-9000 (Fax)

Attorney for Applicant

1230595.1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/997,423
				Filing Date	November 28, 2001
				First Named Inventor	Kimberly A. Gillis
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	102729-12

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BN	WO 02/31209	04/18/2002	Mousses et al.	25, 36-42, 44-45	
	BO	WO 00/55350	09/21/2000	Rosen et al.	3, 10, 83, 341-359, 411-415	
	BP	WO 00/55174	09/21/2000	Rosen et al.	3-4, 12, 32, 78, 347-362, 414-427	

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CO	Database Genbank Online, www.ncbi.nlm.nih.gov , Database Accession No. NM_004117, April 5, 2003	
	CP	Zhu et al., "Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP," <i>Carcinogenesis</i> , Vol. 22, No. 9, September 2001, pp 1399-1402 ✓	
	CQ	Chung et al., "Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells," <i>Carcinogenesis</i> , Vol. 22, No. 8, August 2001, pp 1201 ✓	
	CR	Amler et al., "Dysregulated Expression of Androgen-responsive and Nonresponsive Genes in the Androgen-independent Prostate Cancer Xenograft Model CWR22-R," <i>Cancer Research</i> , Vol. 60, No. 21, November 1, 2000, pp 6134, 6139-6140	
	CS	Nair et al., "Molecular Cloning of Human FKBP51 and Comparisons of Immunophilin Interactions with Hsp90 and Progesterone Receptor," <i>Molecular and Cellular Biology</i> , Vol. 17, No. 2, February 1997, pp 594-595	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.